Buy Hydrea (Hydroxyurea) Online — Bristol-Myers Squibb Ribonucleotide Reductase Inhibitor for CML, Polycythemia Vera, Head & Neck Cancer & Sickle Cell Disease
Hydrea is the original brand-name formulation of Hydroxyurea (international name Hydroxycarbamide) manufactured by Bristol-Myers Squibb — one of the most versatile and longest-established chemotherapy agents in modern medicine. FDA-approved in 1967, Hydrea has crossed nearly 60 years of continuous clinical use and remains unique among cancer therapies for its dual role across oncology AND hematology disciplines. Listed on the WHO Model List of Essential Medicines. Bristol-Myers Squibb also markets Droxia (lower-strength formulation specifically for sickle cell disease in adults), while pediatric sickle cell use internationally is supported by the Siklos formulation (Addmedica). Hydrea's distinctive position spans resistant chronic myeloid leukemia, head and neck cancer adjuvant therapy, recurrent ovarian cancer, melanoma, AND sickle cell disease — the latter through Hydroxyurea's unique ability to induce fetal hemoglobin production.
Pharmacology operates through inhibition of ribonucleotide reductase, the enzyme that converts ribonucleotides to deoxyribonucleotides required for DNA synthesis. Hydroxyurea blocks this conversion at the M2 subunit, halting DNA replication specifically during S-phase of the cell cycle. The result is cytoreduction in rapidly dividing cells — cancer cells, myeloid progenitor cells, and (importantly) erythroid precursors where it triggers a switch toward fetal hemoglobin (HbF) production. This HbF induction is the mechanism behind sickle cell disease benefit. Half-life ranges 3-4 hours with primarily renal excretion.
Hydrea is FDA-approved for resistant chronic myeloid leukemia (CML), locally advanced squamous cell head and neck cancer (with concurrent radiation), melanoma (selective use), recurrent metastatic or inoperable ovarian carcinoma, and sickle cell disease in adults (also Droxia formulation). Established off-label uses include first-line therapy for polycythemia vera, essential thrombocythemia, myelofibrosis, hypereosinophilic syndrome, and severe refractory psoriasis.
Available as Hydrea 500 mg oral capsules. Dosing varies dramatically by indication: cancer typically 20-30 mg/kg/day; sickle cell disease 15-35 mg/kg/day; PV/ET 500-2000 mg/day adjusted by complete blood count response. Always under hematology/oncology supervision.
Clinical evidence: landmark MSH (Multicenter Study of Hydroxyurea) trial established 44% reduction in painful sickle cell crises and 50% reduction in transfusion requirements. STOP and BABY HUG trials extended evidence into pediatric sickle cell populations. For myeloproliferative neoplasms, decades of clinical experience position Hydroxyurea as first-line cytoreductive therapy recommended by NCCN, ELN, and BSH guidelines worldwide.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- CML Chronic Phase: For CML chronic phase cytoreduction;
- Head Neck Cancer Radiation: FDA-approved for locally advanced squamous cell head and neck cancer with concurrent radiation;
- Squamous Cell Head Neck: For squamous cell carcinoma of head and neck adjuvant to radiation;
- Melanoma Selective: FDA-approved selective use in melanoma chemotherapy;
- Ovarian Cancer Recurrent Inoperable: FDA-approved for recurrent metastatic or inoperable ovarian carcinoma;
- Sickle Cell Disease Adults: FDA-approved for sickle cell disease in adults — UNIQUE non-cancer indication, HbF induction;
- Sickle Cell Crisis Prevention: For sickle cell painful crisis prevention — foundational sickle cell therapy;
- Sickle Cell Pediatric Siklos: Pediatric sickle cell disease (Siklos formulation internationally);
- Polycythemia Vera: Off-label FIRST-LINE therapy for polycythemia vera (PV) — established standard;
- Essential Thrombocythemia: Off-label first-line for essential thrombocythemia (ET);
- Myelofibrosis Symptom Control: Off-label for myelofibrosis symptom control (splenomegaly, leukocytosis);
- Myeloproliferative Neoplasms MPN: Foundational cytoreductive therapy for myeloproliferative neoplasms;
- Hypereosinophilic Syndrome: Off-label for hypereosinophilic syndrome;
- Chronic Eosinophilic Leukemia: Off-label for chronic eosinophilic leukemia;
- Psoriasis Severe Refractory: Off-label for severe refractory psoriasis (cytoreduction approach);
- Thrombocytosis MPN: For thrombocytosis in MPN patients with thrombotic risk;
- Erythrocytosis Reduction: For erythrocytosis reduction in polycythemia vera;
- Leukocytosis Cytoreduction: For leukocytosis cytoreduction ? CML and MPN;
- Sickle Cell Anemia Reduction: Reduces transfusion requirements in sickle cell disease (50% reduction per MSH trial);
- HIV Historical Use: Historical HIV use (no longer recommended — superseded by modern HAART);
- Splenectomy Bridge Therapy: Bridge therapy to splenectomy in myeloproliferative disorders.
- Less Head Neck Cancer Progression: Improves locoregional control in advanced squamous cell head and neck cancer with radiation;
- Better Melanoma Response Selective: Selective effective response in melanoma chemotherapy;
- Better Recurrent Ovarian Cancer Outcomes: Effective in recurrent metastatic or inoperable ovarian carcinoma;
- Less Sickle Cell Painful Crises: ⭐ 44% reduction in painful sickle cell crises — MSH landmark trial benefit;
- Less Sickle Cell Transfusion Requirements: 50% reduction in transfusion requirements — MSH benefit;
- Less Sickle Cell Acute Chest Syndrome: Reduces acute chest syndrome frequency in sickle cell disease;
- Less Sickle Cell Hospitalizations: Reduces hospitalizations in sickle cell disease;
- Better Pediatric Sickle Cell Outcomes: Pediatric sickle cell benefit established by BABY HUG, STOP trials (Siklos formulation);
- Better Fetal Hemoglobin Production: ⭐ Induces HbF production — unique pharmacological mechanism in sickle cell;
- Better Polycythemia Vera Control: First-line cytoreductive therapy for polycythemia vera;
- Better Essential Thrombocythemia Control: First-line cytoreductive therapy for essential thrombocythemia;
- Better Myelofibrosis Symptom Control: Improves splenomegaly and leukocytosis symptoms in myelofibrosis;
- Less Thrombotic Risk MPN: Reduces thrombotic risk in myeloproliferative neoplasms through platelet/RBC cytoreduction;
- Better Hypereosinophilic Syndrome Control: Off-label benefit in hypereosinophilic syndrome;
- Better Severe Refractory Psoriasis: Off-label benefit in severe refractory psoriasis through cytoreduction;
- Better Daily Function: Oral once-daily dosing supports return to normal daily activities;
- Better Quality of Life Sickle Cell: Substantial quality of life improvement in sickle cell disease patients;
- Better Compliance Oral: Oral administration improves compliance vs IV chemotherapy;
- Brand Hydrea Bristol Myers: Original Bristol-Myers Squibb brand of Hydroxyurea — foundational agent since 1967;
- Generic Hydroxyurea: Affordable generic Hydroxyurea versions expand global access;
- Droxia BMS Sickle Cell: Droxia formulation (BMS) specifically for sickle cell disease in adults;
- Siklos International Pediatric: Siklos formulation (Addmedica) for pediatric sickle cell internationally;
- Ribonucleotide Reductase Inhibitor: Ribonucleotide reductase inhibitor — blocks DNA synthesis at S-phase;
- Fetal Hemoglobin HbF Induction: Unique HbF induction mechanism — foundation of sickle cell benefit;
- S Phase Specific Cycle Inhibitor: S-phase specific cell cycle inhibitor — targeted cytotoxicity;
- Dual Field Oncology Hematology: ⭐ Dual-field drug — oncology + hematology indications, unique versatility;
- Oral Administration Convenience: Oral capsule administration — patient-friendly chemotherapy delivery;
- MSH Trial Sickle Cell Landmark: Landmark MSH trial — 44% sickle cell crisis reduction, 50% transfusion reduction;
- BABY HUG STOP Pediatric Trials: BABY HUG and STOP trials extended evidence to pediatric sickle cell;
- NCCN ELN Guideline Recommended: NCCN, ELN, BSH guideline-recommended for MPN cytoreduction;
- WHO Essential Medicine: Listed on the WHO Model List of Essential Medicines (oncology + hematology);
- 55 Plus Year Clinical History: 55+ years of clinical use since 1967 — foundational versatile chemotherapy agent.
Generic Hydrea (Hydroxyurea 500 mg) Medication guide:
📖 What Hydrea Is and How It Works
Hydrea is a brand name for hydroxyurea (called hydroxycarbamide in the UK and much of Europe). The drug is old - approved by the US FDA back in 1967 for cancer. Almost six decades later it remains one of the most versatile drugs in haematology, used for four quite different conditions that share nothing except the fact that hydroxyurea helps them.
Hydrea started life as a chemotherapy drug for chronic myeloid leukaemia and various solid tumours. Then in the 1980s researchers noticed something unexpected - the drug reactivated fetal haemoglobin (HbF) in patients treated for other reasons. This observation led to the pivotal MSH trial in 1995 which showed hydroxyurea cuts pain crises in sickle cell disease in half. Today the sickle cell indication is arguably the drug's biggest global impact.
The four main modern uses of Hydrea
- 🩸 Sickle cell disease - the largest global use; adults and children from 9 months onward; disease-modifying therapy
- 🩸 Polycythemia vera and essential thrombocythemia - myeloproliferative neoplasms where hydroxyurea is first-line cytoreductive therapy
- 🧬 Chronic myeloid leukaemia - historical mainstay; largely replaced by tyrosine kinase inhibitors since 2001 but still used for initial cytoreduction or in resource-limited settings
- 🧬 Cytoreduction in acute leukaemia - to lower blast counts before definitive chemotherapy
Hydrea is an oral capsule taken once daily in most protocols. The standard capsule is 500 mg. Dosing is weight-based and titrated against blood counts. Unlike many chemotherapy drugs it does not need IV administration - the drug is taken at home for months or years like any long-term prescription.
Hydrea is on the WHO Model List of Essential Medicines both for cancer and for sickle cell disease. It is one of the few drugs in oncology whose price has stayed low enough that generic versions are affordable worldwide. This matters particularly for sickle cell disease which affects around 300 000 births per year, mostly in low- and middle-income countries.
This guide walks through what Hydrea does, the different clinical contexts where it fits, the practical realities of daily dosing and blood count monitoring, the side effects that matter most (bone marrow suppression, skin effects, leg ulcers), and the long-term issues including secondary cancer risk. Treat it as a companion to what your treating haematology or oncology team tells you.
💊 Why Doctors Prescribe Hydrea Across Many Diseases
The list of conditions where Hydrea is prescribed is unusually broad for a single drug. Understanding your specific indication shapes everything else - the dose, the duration, the monitoring, and what side effects matter most.
Sickle cell disease
The biggest global indication. Hydroxyurea works in sickle cell disease by reactivating fetal haemoglobin (HbF) in red cells. HbF cannot polymerise the way sickle haemoglobin does. Red cells with substantial HbF do not sickle. Pain crises fall by roughly half. Hospital admissions drop. Acute chest syndrome becomes less common. Long-term follow-up shows meaningful mortality reduction. Section 3 covers this in depth.
Polycythemia vera and essential thrombocythemia (MPN)
Myeloproliferative neoplasms where bone marrow produces too many red cells (polycythemia vera) or too many platelets (essential thrombocythemia). Left untreated these cause strokes, heart attacks, and other thrombotic events. Hydroxyurea reduces production - the "cytoreduction" strategy - and cuts thrombosis rates substantially. Section 4 covers this.
Chronic myeloid leukaemia (CML)
Historically the main use. Since imatinib (Gleevec) launched in 2001 and later tyrosine kinase inhibitors (dasatinib, nilotinib, bosutinib, ponatinib) transformed CML treatment, hydroxyurea has largely stepped aside. Modern use is for initial cytoreduction while waiting for TKI response, or in settings where TKIs are unavailable. Section 5 covers the modern positioning.
Other haematology and oncology uses
- Cytoreduction of high white cell counts in acute leukaemia before starting definitive chemotherapy
- Chronic myelomonocytic leukaemia and other overlap disorders
- Occasional use in hypereosinophilic syndrome
- Combined with radiotherapy in head and neck or cervical cancer (rare modern use)
- Occasional off-label use in HIV-associated Kaposi sarcoma
Why one drug for so many diseases
Hydroxyurea is a ribonucleotide reductase inhibitor. It blocks DNA synthesis and slows cell division in any fast-proliferating cell population. In sickle cell disease this quiets the bone marrow and shifts the haemoglobin switch. In MPN and CML it reduces the overproduction. In leukaemia it drops blast counts. Different diseases, same mechanistic hook.
Ask your treating team which specific condition Hydrea has been prescribed for and what the therapy plan looks like - dose, monitoring schedule, expected duration. The plan differs meaningfully across indications.
🩸 Hydrea for Sickle Cell Disease - The Modern Standard
Sickle cell disease is the largest single global use of Hydrea. Since the 1998 US approval and 2017 paediatric extension the drug has become the disease-modifying standard for anyone with symptomatic sickle cell disease, from infants through adults.
Who benefits
Current guidelines recommend hydroxyurea for all children with sickle cell anaemia (HbSS or HbS beta-zero thalassaemia) from age 9 months, and for adults with:
- Three or more pain crises per year
- History of acute chest syndrome
- Severe symptomatic anaemia
- Chronic kidney disease
- Recurrent priapism
- Consideration in essentially all symptomatic HbSS/HbS-beta-zero clients
What the trials showed
The MSH trial (Charache et al. NEJM 1995) enrolled 299 adults with severe sickle cell disease. Hydroxyurea reduced:
- 🟢 Painful crises by 50 percent
- 🟢 Hospital admissions by 50 percent
- 🟢 Acute chest syndrome by 50 percent
- 🟢 Blood transfusion needs by 50 percent
Long-term follow-up (Steinberg et al. Am J Hematol 2010) showed a 40 percent reduction in mortality over 17.5 years. The BABY HUG trial (Wang et al. Lancet 2011) established safety and efficacy in infants aged 9-18 months. The REACH trial (Tshilolo et al. NEJM 2019) confirmed benefit in African children.
How Hydrea works in sickle cell disease
- Reactivates fetal haemoglobin (HbF) - the main mechanism; HbF-containing red cells do not sickle
- Reduces neutrophil and platelet counts - lowers baseline inflammation and vaso-occlusion
- Increases nitric oxide availability - improves vasodilation
- Improves red cell hydration - less prone to sickling
- Reduces adhesion molecule expression on red cells and endothelium
Typical dosing in sickle cell disease
| Population | Starting dose | Target maximum tolerated dose |
|---|---|---|
| Adults | 15 mg/kg/day | Up to 35 mg/kg/day |
| Children | 20 mg/kg/day | Up to 35 mg/kg/day |
Hydrea for sickle cell disease is disease-modifying, not curative
The drug does not eliminate sickle haemoglobin - it just reduces the fraction that matters clinically. Curative options are haematopoietic stem cell transplant and, since 2023, gene therapy (Casgevy exa-cel, Lyfgenia lovo-cel). These are still limited to specific centres and populations. Hydroxyurea remains the accessible disease-modifying option for the majority of sickle cell clients worldwide.
🩸 Hydrea for Polycythemia Vera and Essential Thrombocythemia
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms - bone marrow disorders where too many red cells or too many platelets are produced. Untreated they cause thrombosis, bleeding, and disease progression. Hydroxyurea is first-line cytoreductive therapy for higher-risk clients in both diseases.
Polycythemia vera (PV)
Nearly always driven by JAK2 V617F mutation. Bone marrow overproduces red cells; haematocrit climbs; blood becomes viscous; thrombosis risk rises substantially. Standard management:
- Low-dose aspirin - reduces thrombosis (ECLAP trial)
- Therapeutic venesection to keep haematocrit under 45 percent
- Hydroxyurea cytoreduction in higher-risk clients (age over 60, prior thrombosis) - typical target 15-20 mg/kg/day, adjusted by counts
- Ruxolitinib or interferon-alfa as alternatives when hydroxyurea fails or is not tolerated
Essential thrombocythemia (ET)
Bone marrow overproduces platelets. Driven by JAK2, CALR, or MPL mutations. Thrombosis is the main risk. Standard management:
- Low-dose aspirin - reduces microvascular symptoms and some thrombosis
- Hydroxyurea cytoreduction in higher-risk clients (age over 60, prior thrombosis, extreme thrombocytosis)
- Anagrelide - alternative platelet-reducing agent; PT-1 trial showed hydroxyurea superior for arterial thrombosis prevention
- Interferon-alfa (peginterferon) - preferred in younger clients and during pregnancy
- Ruxolitinib - JAK inhibitor for resistant or intolerant clients
The ECLAP and PT-1 evidence
The ECLAP trial (Landolfi et al. NEJM 2004) in polycythemia vera established low-dose aspirin as standard. The PT-1 trial (Harrison et al. NEJM 2005) in essential thrombocythemia compared hydroxyurea plus aspirin with anagrelide plus aspirin. Hydroxyurea was superior for arterial thrombosis prevention though similar overall for combined thrombosis endpoints. Since then hydroxyurea has been first-line cytoreduction in most higher-risk MPN clients.
Practical MPN dosing
- Starting dose typically 15-20 mg/kg/day
- Titrated against platelet count (ET) or haematocrit (PV) with WBC monitoring
- Long-term daily therapy - years or decades in most cases
- Full blood count monitoring monthly to three-monthly depending on stability
- Watch for hydroxyurea intolerance or resistance (Section 31)
MPN care is a lifelong process. Hydroxyurea is one piece of a broader plan that includes aspirin, cardiovascular risk management, and periodic assessment for disease progression to myelofibrosis or acute leukaemia. Regular haematology follow-up is essential.
🧬 Hydrea in Chronic Myeloid Leukaemia Today
Chronic myeloid leukaemia (CML) was hydroxyurea's original main use in oncology. The picture changed dramatically in 2001 when imatinib (Gleevec) - the first tyrosine kinase inhibitor targeting the BCR-ABL fusion protein - transformed CML from a fatal disease into a chronic manageable one.
Where Hydrea sits in CML today
- Initial cytoreduction - while BCR-ABL testing confirms diagnosis and while waiting for TKI response, hydroxyurea rapidly reduces very high white cell counts
- Blast crisis or accelerated phase - hydroxyurea for cytoreduction alongside other therapy
- Resource-limited settings where TKIs are unaffordable - hydroxyurea remains a maintenance option for chronic phase
- Older or frailer clients who cannot tolerate TKIs, or where TKI side effects outweigh benefit given competing comorbidities
- TKI intolerance or failure where hydroxyurea provides temporary control while planning next steps
The TKI landscape that displaced Hydrea in CML
- Imatinib (Gleevec) - first-generation TKI; launched 2001; standard first-line for most
- Dasatinib (Sprycel) - second-generation; first- or second-line
- Nilotinib (Tasigna) - second-generation; first- or second-line
- Bosutinib (Bosulif) - second-generation; second-line typically
- Ponatinib (Iclusig) - third-generation; resistance settings including T315I mutation
- Asciminib (Scemblix) - allosteric BCR-ABL inhibitor; approved 2021 for resistant disease
The dramatic improvement in CML outcomes over the last two decades is one of oncology's success stories - five-year survival on TKI therapy exceeds 90 percent in chronic phase disease. Hydroxyurea remains useful for specific niches but the days of chronic monotherapy with hydroxyurea for CML are largely gone.
Practical dosing when Hydrea is used in CML
- Initial cytoreduction: 40-80 mg/kg/day, tapering as counts fall
- Maintenance (when used): typically 15-30 mg/kg/day titrated against counts
- Frequent blood count monitoring - weekly initially, then monthly
- Watch for myelosuppression, especially in older clients
If Hydrea has been prescribed to you for CML, ask whether it is bridging therapy while waiting for a TKI, or a chosen chronic strategy given specific circumstances. The answer changes what to expect.
🔬 How Hydroxyurea Blocks Ribonucleotide Reductase
Hydroxyurea works through a simple biochemical mechanism that explains almost all its effects across the different diseases it treats.
The core mechanism
Hydroxyurea is a ribonucleotide reductase inhibitor. Ribonucleotide reductase is the enzyme that converts ribonucleotides (the building blocks of RNA) into deoxyribonucleotides (the building blocks of DNA). Cells about to divide need deoxyribonucleotides to duplicate their DNA. Block the enzyme, and DNA synthesis stalls.
Consequences of the block
- Rapidly dividing cells (bone marrow, gut lining, hair follicles) are most affected
- Cells arrest in the S phase of cell cycle
- Bone marrow production of white cells, red cells, and platelets falls
- In sickle cell disease, the marrow stress activates the fetal haemoglobin gene programme - HbF production rises
- In MPN and leukaemia, the overproduction of cells is suppressed
Pharmacokinetics that shape dosing
| Feature | Detail |
|---|---|
| Bioavailability | Excellent oral absorption |
| Half-life | 3-4 hours |
| Dosing frequency | Once daily in most protocols |
| Metabolism | Approximately 60 percent metabolised |
| Excretion | Renal (mostly unchanged drug) |
| Genetic variability | Individual response varies substantially |
Once-daily dosing despite short half-life
The 3-4 hour half-life would normally suggest multiple daily doses. Hydroxyurea works despite once-daily dosing because the pharmacological effect (S-phase arrest) lasts much longer than the drug is present in blood. Cells caught in the S phase during peak drug exposure stay arrested for hours after the drug has cleared. This is why once-daily dosing is effective.
The clinical picture across diseases traces back to this single molecular action. What differs is which cell population is being targeted and what secondary effect (HbF induction versus cell reduction) matters most for the specific disease.
🧬 Hydrea and Fetal Haemoglobin Induction
Fetal haemoglobin (HbF) is the star of the sickle cell disease story. Understanding HbF induction is central to understanding why hydroxyurea works in this condition.
The haemoglobin switch
Before birth, fetal red cells make fetal haemoglobin (HbF) - a specific tetramer of alpha and gamma globin chains. Around birth the body switches from HbF to adult haemoglobin (HbA) - alpha and beta chains. By age 6 months HbF has fallen to less than 5 percent of total haemoglobin. In sickle cell disease the beta globin gene is mutated, producing sickle haemoglobin (HbS) that polymerises and deforms red cells under low-oxygen conditions.
Why HbF protects
HbF-containing red cells do not polymerise HbS the way pure HbS red cells do. HbF disrupts the sickle polymer. Red cells with substantial HbF (typically over 20-30 percent) resist sickling under most physiological conditions. This is why some individuals with hereditary persistence of fetal haemoglobin (HPFH) - a naturally occurring genetic variant that keeps HbF high after infancy - have very mild sickle cell disease even when they have inherited the same HbSS genotype.
How hydroxyurea reactivates HbF
The exact molecular pathway is still not fully worked out but several mechanisms contribute:
- Marrow stress from S-phase arrest triggers stress erythropoiesis which favours HbF production
- Increased nitric oxide signalling upregulates gamma globin gene expression
- Changes in transcription factor balance shift toward gamma globin
- Cell cycle effects favour F-cell selection
Practical HbF response
- Baseline HbF in adults with sickle cell disease: typically 3-8 percent
- On hydroxyurea at maximum tolerated dose: often rises to 15-30 percent or higher
- Response takes 3-6 months to become fully apparent
- Higher HbF correlates with fewer clinical events
- Some clients are "super-responders" with HbF rising above 30 percent
- A minority of clients respond poorly - genetic variants may predict this
Newer HbF-directed therapies
Hydroxyurea has been joined by other HbF-directed strategies in recent years. Gene therapies (Casgevy, Lyfgenia - approved 2023) target the HbF gene programme directly, either editing or knocking out BCL11A (the master repressor of HbF). These are transformative for individuals who can access them, but hydroxyurea remains the accessible foundation of sickle cell care globally.
⚖️ The Landmark MSH Trial in Sickle Cell
The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) trial defined the modern use of Hydrea in sickle cell disease. Published in the New England Journal of Medicine in 1995 by Samuel Charache and colleagues, it changed the standard of care overnight.
The trial in short
- 299 adults with severe sickle cell anaemia (HbSS)
- History of at least 3 painful crises per year
- Randomised to hydroxyurea (dose titrated to maximum tolerated) or placebo
- Primary outcome: rate of painful crises
- Trial stopped early after 21 months due to clear benefit
The key results
- 🟢 Painful crises reduced by 50 percent
- 🟢 Hospital admissions reduced by 50 percent
- 🟢 Acute chest syndrome reduced by 50 percent
- 🟢 Blood transfusion requirements reduced by 50 percent
- 🟢 Tolerability generally acceptable
The mortality story
Long-term follow-up of MSH participants published by Steinberg and colleagues in 2010 showed a 40 percent reduction in mortality among clients who had taken hydroxyurea, extending over 17.5 years of observation. This is a rare example in haematology where a single drug delivers measurable life-extension in a chronic disease.
Follow-on trials extending the evidence base
- Pediatric Hydroxyurea Group (PHG) studies - extended evidence to children
- BABY HUG (Wang et al. Lancet 2011) - 193 infants aged 9-18 months; safe and effective in the youngest population
- SWiTCH (Ware et al. Blood 2012) - hydroxyurea versus transfusion in children with prior stroke
- TCD With Transfusions Changing to Hydroxyurea (TWiTCH, NEJM 2016) - non-inferiority of hydroxyurea versus transfusions for primary stroke prevention
- REACH (Tshilolo et al. NEJM 2019) - safety and efficacy in African children (real-world settings)
Practice impact
MSH led directly to the 1998 FDA approval of hydroxyurea for sickle cell disease. The 2017 paediatric approval followed BABY HUG. Current NHLBI and ASH guidelines strongly recommend hydroxyurea for essentially all symptomatic children and adults with sickle cell anaemia. It is one of the clearest examples of a landmark trial changing global practice for a specific disease.
📏 Choosing Your Hydrea Dose - Weight-Based Titration
Hydrea dose depends on the disease being treated and the individual client. Doses are weight-based, titrated against blood counts, and often escalated over months to find the maximum tolerated dose (MTD).
Typical doses by indication
| Indication | Starting dose | Target dose |
|---|---|---|
| Adult sickle cell disease | 15 mg/kg/day | Up to 35 mg/kg/day (MTD) |
| Paediatric sickle cell disease | 20 mg/kg/day | Up to 35 mg/kg/day (MTD) |
| Polycythemia vera / ET | 15-20 mg/kg/day | Titrated by counts |
| CML initial cytoreduction | 40-80 mg/kg/day | Taper as counts fall |
| CML maintenance (rare) | 15-30 mg/kg/day | Titrated by counts |
The maximum tolerated dose (MTD) concept in sickle cell
In sickle cell disease, higher hydroxyurea doses produce better HbF response and better clinical benefit. The strategy is dose escalation to maximum tolerated dose - typically 20 mg/kg/day starting, then increases of 5 mg/kg every 8 weeks based on tolerability, aiming for the highest dose that does not cause unacceptable myelosuppression. Absolute neutrophil count above 2 x10^9/L, platelets above 80 x10^9/L, and haemoglobin above 5.3 g/dL are common thresholds for tolerability during titration.
Dose adjustments
- Renal impairment - reduce dose (renally excreted); halve for eGFR under 60; further adjust for lower eGFR
- Cytopenia - hold or reduce dose per protocol thresholds
- Skin ulcers on treatment - reduce dose or stop
- Older or frailer clients - lower starting dose, slower titration
- Recovery from severe illness - hold or restart at lower dose
Do not adjust dose yourself
The dose titration is protocol-driven based on blood count trends. Self-adjustment risks either inadequate disease control (under-dosing) or serious myelosuppression (over-dosing). Any dose change should come from the treating haematology team.
📅 Your First Weeks Starting Hydrea Therapy
What actually happens in the first weeks on Hydrea depends on the indication but shares some common features across diseases.
Days 1-7. The drug is absorbed quickly. Blood levels build to steady state within a few days. Cell cycle effects begin within hours of the first doses. Blood counts do not change dramatically yet - the effect of hydroxyurea on the marrow takes 2-6 weeks to become clinically visible.
Weeks 2-4. First blood test point. White cells and platelets start to fall. Haemoglobin may drop slightly. In sickle cell disease, HbF has not risen meaningfully yet - that response takes 3-6 months.
Weeks 4-8. The pattern of cytopenia establishes. Dose titration begins in sickle cell disease if tolerability allows. In MPN, target platelet or haematocrit levels are approached. In cytoreduction for CML or acute leukaemia, high white counts fall quickly.
Baseline tests before starting
- 💉 Full blood count with reticulocyte count
- 💉 Renal function (creatinine, eGFR) and electrolytes
- 💉 Liver function tests
- 💉 In sickle cell: baseline HbF percentage, MCV
- 💉 In MPN: JAK2/CALR/MPL genotype if not already known
- 💉 Pregnancy test in women of reproductive age (mandatory - drug is teratogenic)
- 💉 Vaccination review (Section 27)
Common early experiences
- Little dramatic change in first days
- Occasional mild nausea; usually settles
- Occasional headache
- Slight tiredness
- Blood counts begin to shift by week 2-4
- MCV (red cell size) typically rises - characteristic hydroxyurea marker of drug effect
Signs to report to the team
- 🔴 Fever above 38 C - may need urgent blood count check
- 🔴 Unusual bruising or bleeding
- 🔴 New leg ulcer or skin breakdown
- 🔴 Severe nausea or vomiting
- 🔴 New shortness of breath - possible pulmonary reaction
- 🔴 Confirmed pregnancy
- 🔴 Severe rash
Most clients complete the first weeks smoothly and settle into the long-term monitoring rhythm. Sickle cell clients feel the clinical benefit (fewer crises) over months rather than days, so patience with the response timeline is part of the therapy.
⏰ Timing and How to Take Hydrea Each Day
Hydrea is a once-daily oral drug in most protocols. The timing is flexible. Consistency matters more than the exact clock time.
Basic dosing rules
- Once daily is standard
- Same time each day, roughly within 1-2 hours
- With or without food - your choice, be consistent
- Swallow whole with water - do not open capsules unless specifically instructed
- Morning or evening both work
Handling hydroxyurea capsules safely
Hydrea is a cytotoxic drug. Standard cytotoxic handling precautions apply:
- 🔴 Do not open, crush, or chew capsules unless specifically directed
- 🔴 Wash hands after handling the capsules
- 🔴 If a capsule breaks or spills, use gloves to clean up and wash the area thoroughly
- 🔴 Pregnant caregivers should avoid direct handling
- 🔴 Store in a safe place away from children
Anchor the dose to a daily habit
- With breakfast - simplest for most people
- Weekly pillbox refilled every Sunday - single most effective adherence tool
- Phone reminder labelled "Hydrea" or "hydroxyurea"
- Keep the pack visible - kitchen counter beats bathroom cabinet
- Refill prescription 2 weeks before running out
- Travel with extra supply
For clients unable to swallow capsules
Children and clients who cannot swallow capsules may need alternative approaches. Options include the specific Siklos (deferiprone-free hydroxyurea) tablets which are scored and can be halved, or specialist compounded liquid formulations from centres that prepare these safely. Do not open standard Hydrea capsules yourself - the cytotoxic contents need special handling. Discuss with the treating team and pharmacy.
Section 23 covers what to do about missed doses. Short version: within 12 hours of usual time, take it; more than 12 hours late, skip and take next dose as usual. Never double up.
🍽️ Food, Diet and Fluids on Hydrea
Diet on Hydrea does not need to be dramatic. Food does not meaningfully affect drug absorption. But fluid intake matters, and some general nutrition points support long-term therapy.
Fluid intake
- 💧 Aim for 2-3 litres of fluid daily
- 💧 Particularly important in sickle cell disease where dehydration triggers crises
- 💧 Adequate fluids also support kidney excretion of the drug
- 💧 Water, weak tea, diluted juice all count
General food rules on Hydrea
- Take capsules with or without food - your choice, be consistent
- No specific grapefruit interaction unlike some cancer drugs
- Adequate protein - 1.0-1.2 g/kg body weight daily; supports blood cell production
- Folate-rich foods (leafy greens, legumes, fortified cereals) - hydroxyurea can occasionally lower folate levels
- Some centres prescribe folic acid 5 mg daily alongside hydroxyurea
- Iron intake - not routinely restricted; discuss with team
Nutrition considerations by indication
- Sickle cell disease: hydration crucial; folic acid often supplemented; adequate calorie intake matters for growth in paediatric clients
- MPN: Mediterranean-style diet supports cardiovascular risk management alongside cytoreduction
- CML and acute leukaemia: nutritional support during cytoreduction phase; oncology dietitian if intake is difficult
Supplements to avoid or check
- 🔴 St John's Wort - enzyme induction may affect drug levels
- 🔴 Kava, comfrey, chaparral - hepatotoxic potential
- 🔴 Untested "blood building" or "cancer wellness" formulations
- 🔴 High-dose vitamin C (megadoses) - can interact with iron metabolism in some settings
Standard multivitamins, folic acid, and modest calcium and vitamin D are fine. Anything marketed for immune boosting or blood building should be checked with the treating team first.
🍷 Alcohol Rules During Hydrea Therapy
Alcohol during Hydrea therapy is worth thinking about even though there is no dramatic interaction. Hydrea is a cytotoxic drug with cumulative effects; alcohol is metabolically stressful; both together add unnecessary load.
Sensible position
- 🟡 Moderate drinking is generally compatible with long-term Hydrea for stable clients
- 🟡 Up to 14 units per week, spread out with alcohol-free days (UK CMO guidance)
- 🔴 No binge drinking
- 🔴 Avoid alcohol if LFTs are elevated
- 🔴 Abstinence in significant liver disease
Special consideration in sickle cell disease
In sickle cell clients, alcohol has additional issues beyond the general population. Dehydration from alcohol can trigger vaso-occlusive pain crises. Alcohol interferes with sleep, and poor sleep increases crisis risk. Chronic heavy alcohol use worsens liver function, which many sickle cell adults already have complications with. The recommendation for many sickle cell adults on Hydrea is minimal or no alcohol - this comes as much from the sickle cell context as from the drug itself.
Abstinence indicated when
- 🔴 Existing liver disease of any cause
- 🔴 History of alcohol dependence
- 🔴 LFT abnormalities on routine monitoring
- 🔴 Sickle cell disease with previous alcohol-triggered crises
- 🔴 Advanced MPN with disease progression
- 🔴 Concurrent hepatotoxic drugs
The alcohol conversation on Hydrea is more about the underlying disease than the drug itself. For most stable clients on Hydrea for MPN or CML, moderate drinking is acceptable. For sickle cell clients the threshold is stricter because dehydration risk matters more.
🚨 Hydrea Side Effects - Complete Overview
Hydrea has a well-characterised side effect profile after six decades of use. Most effects trace back to the same mechanism - suppression of DNA synthesis in fast-dividing cells. Understanding what to expect helps distinguish routine side effects from serious warning signs.
Common (over 10 percent)
- 🟡 Myelosuppression - lower white cells, platelets, red cells; the intended effect at higher doses and the dose-limiting toxicity; Section 15
- 🟡 Increased MCV (macrocytosis) - large red cells; a marker of drug effect rather than a problem
- 🟡 Mild GI upset - nausea, occasional diarrhoea; Section 17
- 🟡 Skin hyperpigmentation and nail changes - Section 18
Less common (1-10 percent)
- 🟡 Hair thinning - not complete alopecia typically; Section 18
- 🟡 Fatigue
- 🟡 Leg ulcers - characteristic hydroxyurea complication; Section 16
- 🟡 Rash and skin sensitivity
- 🟡 Photosensitivity
- 🟡 Elevated liver enzymes - usually modest
- 🟡 Fever reaction (hypersensitivity) - Section 19
Uncommon
- 🟠 Pulmonary toxicity - interstitial lung disease, pneumonitis; Section 19
- 🟠 Cutaneous vasculitis, aphthous ulcers
- 🟠 Neurological symptoms - headache, dizziness, drowsiness
- 🟠 Renal impairment
- 🟠 Skin cancer with long-term use - Section 21
Rare but serious - urgent care needed
- 🔴 Severe neutropenia with fever - infection risk; emergency
- 🔴 Severe thrombocytopenia with bleeding
- 🔴 Interstitial lung disease - progressive breathlessness, dry cough
- 🔴 Severe skin reaction - blistering, peeling, mucosal involvement
- 🔴 Non-healing leg ulcer - may need drug stop
- 🔴 New non-melanoma skin cancer
- 🔴 Progressive fatigue with new cytopenias - possible transformation to MDS/AML
Long-term issues to know
- Skin cancer risk with long-term use, especially in sun-exposed skin
- Non-melanoma skin cancers (BCC, SCC) elevated on prolonged therapy
- Secondary MDS or AML - low but real risk; Section 21
- Fertility effects (Section 20)
- Long-term leg ulcers can persist after stopping
Most clients tolerate long-term Hydrea well. Blood count monitoring is the safety net that catches problems early. Skin surveillance and sun protection matter more the longer you take the drug.
🩸 Myelosuppression and Blood Count Monitoring on Hydrea
Myelosuppression is both the intended effect of Hydrea (in MPN, CML, and cytoreduction) and its main dose-limiting toxicity. The blood count monitoring schedule exists to catch cytopenias early and adjust dose accordingly.
What happens to blood counts
- Neutrophils - fall progressively over weeks; dose-related
- Platelets - fall similarly; sometimes faster than neutrophils
- Haemoglobin - drops modestly in most; more pronounced at higher doses
- MCV - rises (macrocytosis) - characteristic hydroxyurea marker
- Reticulocytes - fall
- HbF percentage - rises over 3-6 months in sickle cell clients
Standard monitoring schedule
| When | What |
|---|---|
| Baseline | Full blood count, reticulocytes, renal and liver function |
| Every 2 weeks first 8 weeks | Full blood count |
| Monthly during dose titration | FBC, renal function |
| Every 2-3 months when stable | FBC, renal function, HbF in sickle cell |
| After dose change | Weekly FBC for 4 weeks |
Cytopenia thresholds for holding or reducing dose
- Neutrophils below 2 x10^9/L in sickle cell - typically hold and reduce next dose
- Platelets below 80 x10^9/L - hold and reduce
- Haemoglobin below 5.3 g/dL (or drop of over 20 percent from baseline) - hold in sickle cell
- Reticulocytes below 80 x10^9/L with haemoglobin below 9 g/dL - hold
- Different thresholds apply for MPN and CML - guided by treatment target rather than sickle cell rules
Infection during cytopenia is an emergency
If neutrophils are low and you develop fever above 38 C, this is a medical emergency. Contact the treating team immediately and expect same-day hospital assessment. Do not wait to see if it settles.
The monitoring is not optional. Missing scheduled blood tests removes the safety net that makes Hydrea use responsible. Attend appointments and communicate any new symptoms between them.
🦵 Skin Effects and Leg Ulcers on Hydrea
Skin effects are one of the most distinctive hydroxyurea-specific issues. Some (hyperpigmentation, nail changes) are largely cosmetic. Leg ulcers are functionally serious and can be difficult to heal even after stopping the drug.
Common skin changes
- Hyperpigmentation - darkening of skin, nail beds, oral mucosa; usually mild and reversible
- Skin atrophy on hands and forearms with long-term use
- Dry skin - responsive to moisturisers
- Photosensitivity - burn more easily; sun protection matters
- Nail changes - dark bands, brittleness (melanonychia)
- Aphthous ulcers in mouth - occasional
Leg ulcers - a specific hydroxyurea complication
Hydroxyurea-associated leg ulcers are characteristic:
- 🔴 Typically appear on lower legs, especially around the malleoli (ankle bones)
- 🔴 Painful, punched-out appearance
- 🔴 Slow to heal even with optimal wound care
- 🔴 More common with long-term use (over 5 years)
- 🔴 Often need Hydrea to be stopped for healing to progress
- 🔴 Can persist for months even after drug discontinuation
Managing leg ulcers
- Report any new leg lesion to the treating team promptly
- Wound care under specialist supervision
- Compression bandaging where appropriate
- Rule out other causes (venous disease, arterial disease, infection, sickle cell ulcer in SCD clients)
- Dose reduction or drug stop often needed for healing
- Switch to alternative therapy if ulcer persists
Prevention basics
- Daily skin moisturiser on legs and hands
- Protect legs from minor trauma - avoid scratches, bumps
- Well-fitting shoes and socks
- Manage any underlying venous disease
- Sun protection - SPF 30+ on exposed skin daily
- Regular skin surveillance for new lesions or non-healing wounds
Skin changes on Hydrea are usually manageable. Leg ulcers are the exception - they deserve prompt attention and often require drug adjustment. Do not ignore a new leg lesion assuming it will heal on its own.
🤢 Nausea and GI Side Effects on Hydrea
Gastrointestinal side effects on Hydrea are usually mild and manageable. Unlike many chemotherapy drugs, hydroxyurea does not typically cause the severe nausea that requires major anti-emetic support.
Common GI symptoms
- Mild nausea - most common; usually transient
- Occasional vomiting - less common
- Loss of appetite
- Constipation or occasional diarrhoea
- Mouth ulcers (aphthous) - occasional
- Metallic taste in some clients
Practical management
- 🟢 Take with food if nauseated - most clients tolerate this
- 🟢 Small frequent meals
- 🟢 Cold foods tolerate better than hot for some
- 🟢 Ginger tea or sweets for mild nausea
- 🟢 Ondansetron or metoclopramide as needed for persistent nausea
- 🟢 Loperamide for troublesome diarrhoea
- 🟢 Adequate hydration
- 🟢 Bland foods during flare episodes
When to report GI symptoms
- 🔴 Persistent vomiting beyond 24 hours despite anti-emetics
- 🔴 Cannot keep tablets down for 24 hours
- 🔴 Signs of dehydration
- 🔴 Severe abdominal pain
- 🔴 Bloody diarrhoea
- 🔴 Fever with GI symptoms
- 🔴 Severe mucositis preventing eating
GI symptoms usually settle within the first few weeks or respond to dose reduction if persistent. Rarely they force switching to alternative therapy.
💓 Hair Thinning and Nail Changes on Hydrea
Hair and nail changes on Hydrea are common but usually cosmetic rather than functionally serious. Understanding what to expect avoids unnecessary alarm.
Hair changes
- Thinning rather than complete alopecia - unlike some chemotherapy drugs
- Affects scalp hair, sometimes body hair
- Onset gradual over months
- Usually mild - not visibly bald
- Reversible on stopping
- Hair texture may change - finer, drier
Nail changes
- Melanonychia - dark bands or diffuse darkening of nail beds; harmless but visible
- Beau lines - horizontal ridges reflecting temporary nail growth arrest
- Brittleness with long-term use
- Slower nail growth
- Reversible on stopping (over months)
Practical care
- Gentle hair care - avoid harsh chemicals, heat styling
- Cotton pillowcases reduce hair friction
- Moisturiser on nails to reduce brittleness
- Trim nails regularly - avoid nail extensions if brittle
- Any unusual new pigmented lesion under nail - report; could be subungual melanoma unrelated to Hydrea
These changes are usually accepted as part of long-term therapy rather than reasons to stop. They fade over months after discontinuation. If a specific hair or nail change is unusual (asymmetric pigmentation, growing lesion), report it for clinical assessment.
🫁 Fever Reactions and Pulmonary Toxicity on Hydrea
Two specific reactions to Hydrea deserve their own section because they can be serious and are easily missed - the hydroxyurea fever reaction and pulmonary toxicity.
Hydroxyurea fever reaction
A drug-related fever that mimics infection. Features:
- High fever, sometimes with chills
- Onset within days to weeks of starting Hydrea, or after dose escalation
- Sometimes accompanied by rash
- May include GI symptoms, lung symptoms, or joint pains
- Blood cultures usually negative
- Resolves within 24-48 hours of stopping the drug
- Recurs on rechallenge
The management dilemma
Fever on Hydrea must be treated as potential infection until proven otherwise - especially in clients with cytopenias. Broad-spectrum antibiotics, blood cultures, source hunt. If cultures stay negative and fever resolves rapidly on stopping Hydrea, the diagnosis is the drug reaction. Rechallenge is not usually attempted - reintroduction typically produces the same reaction. Switch to alternative therapy.
Pulmonary toxicity
Rare but serious. Interstitial lung disease or pneumonitis can develop. Features:
- Progressive breathlessness
- Dry cough
- Sometimes fever
- Chest imaging shows interstitial infiltrates
- Lung function tests show restrictive pattern with reduced diffusion
- Onset variable - weeks to months to years into therapy
Emergency symptoms - stop and seek urgent care
- 🔴 New or rapidly worsening breathlessness
- 🔴 New dry persistent cough
- 🔴 Fever with lung symptoms
- 🔴 Chest pain
- 🔴 Oxygen saturation dropping
Pulmonary toxicity from Hydrea needs urgent respiratory assessment - CT chest, lung function, sometimes bronchoscopy. Treatment involves stopping Hydrea and often high-dose steroids. Rechallenge is not attempted.
Both fever reaction and pulmonary toxicity are uncommon but the consequences of missing them are serious. Any unexplained fever or new respiratory symptoms on Hydrea warrant medical review beyond routine.
👶 Fertility and Reproductive Effects of Hydrea
Fertility effects of Hydrea are important and often under-discussed. The drug can affect both male and female fertility and is teratogenic in pregnancy. Reproductive planning matters throughout therapy.
Fertility summary
- In men: reversible reduction in sperm production; azoospermia possible at high doses; usually recovers after stopping
- In women: ovarian function typically preserved; occasional menstrual irregularity
- Teratogenic: demonstrated in animal studies; documented human harm; contraception mandatory
- Effect on fetal haemoglobin in offspring: not applicable; drug does not transmit
Fertility preservation for men
- Discuss sperm banking before starting long-term high-dose therapy
- Especially relevant for young men with sickle cell disease, MPN, or CML expecting years of therapy
- Sperm counts typically recover 3-12 months after stopping the drug
- Recovery may be incomplete in some clients
Contraception rules
- Women of reproductive age: reliable contraception during therapy and for 6-12 months after
- Men of reproductive age: reliable contraception during therapy and for at least 6 months after
- IUDs, hormonal contraception, or barrier methods depending on individual situation
- Do not rely on reduced fertility from the drug as contraception
- Discuss contraception at the pre-treatment appointment
Pregnancy contraindication
Hydrea is teratogenic and pregnancy while on therapy carries a real risk of fetal harm. Sections 28 and 29 cover pregnancy and breastfeeding in detail. Do not become pregnant while taking Hydrea. If pregnancy is confirmed on Hydrea, contact the treating team immediately for specialist review.
For sickle cell clients particularly, pregnancy planning is a bigger conversation - the disease itself carries pregnancy risks and hydroxyurea therapy needs specific management around conception. This is a multidisciplinary discussion that should be had well before conception, not after.
⚠️ Secondary Cancer Risk on Long-Term Hydrea
Long-term hydroxyurea use carries some cancer risk that is worth understanding. IARC classifies hydroxyurea as a Group 2A probable carcinogen. The absolute risk in most contexts is small but not zero and warrants awareness and surveillance.
Main long-term cancer concerns
- 🟡 Non-melanoma skin cancer (BCC, SCC) - real risk with long-term use, especially in sun-exposed skin
- 🟡 Secondary MDS or AML - transformation risk in MPN clients on hydroxyurea; hard to separate from underlying disease trajectory
- 🟡 Solid tumours - modest overall increase in some cohort studies
The MPN transformation debate
Polycythemia vera and essential thrombocythemia carry a baseline risk of transformation to myelofibrosis or acute leukaemia - independent of therapy. Whether hydroxyurea increases this risk beyond baseline has been debated for decades. Most contemporary evidence suggests hydroxyurea is not more leukemogenic than other cytoreductive agents at standard doses, but combined use with alkylators or radiotherapy increases risk substantially. Modern practice avoids alkylator combinations where possible.
Sickle cell disease context
Long-term follow-up of MSH participants and other sickle cell cohorts has not shown a clear excess cancer risk from hydroxyurea in this population. The mortality benefit from the drug substantially outweighs any theoretical cancer risk. This is different from the MPN context where the underlying disease itself has malignant potential.
Long-term surveillance
- Yearly full skin check - dermatology referral if any suspicious lesion
- Daily sun protection - SPF 30+ on exposed skin; hats and long sleeves in sunny conditions
- Any new non-healing skin lesion - immediate review, especially in sun-exposed sites
- Full blood count monitoring continues throughout therapy - watch for new cytopenia patterns suggesting MDS transformation
- Note hydroxyurea exposure permanently in medical record
- Age-appropriate standard cancer screening continues; do not skip mammograms, colonoscopy, cervical smears
- Smoking cessation - reduces cancer risks generally
Long-term surveillance and sun protection are the practical protective measures. In individual clients the risk-benefit calculation is usually strongly in favour of continuing hydroxyurea (for sickle cell) or accepting the modest cancer risk as part of MPN management. The absolute numbers matter more than the classification.
💉 Hydrea Drug Interactions Worth Knowing
Hydrea has a modest drug interaction profile. Most interactions involve additive effects with other myelosuppressive drugs or vaccine considerations.
Serious - avoid or manage carefully
- 🔴 Live vaccines - contraindicated during Hydrea; risk of severe infection
- 🔴 Other cytotoxic chemotherapy - additive myelosuppression and secondary cancer risk
- 🔴 Alkylating agents combined long-term - specifically raises AML transformation risk in MPN
- 🔴 Didanosine (antiretroviral) - severe pancreatitis and lactic acidosis reported when combined
- 🔴 Stavudine (antiretroviral) - similar concerns; combinations largely obsolete anyway
- 🔴 Interferon-alfa - occasional cutaneous vasculitis and leg ulcers when combined
Moderate - inform prescriber
- Other immunosuppressants (methotrexate, azathioprine, mycophenolate) - additive infection risk
- Zidovudine - additive haematological toxicity
- Radiotherapy - additive myelosuppression and cutaneous toxicity
- Bactrim (co-trimoxazole) - additive myelosuppression at long courses
- Anti-uric-acid drugs - hydroxyurea can raise uric acid; discuss
Usually safe together
- Inactivated vaccines - flu, pneumococcal, COVID, Shingrix - all recommended
- Paracetamol at standard doses
- Most antibiotics except long courses of co-trimoxazole
- Standard antihypertensives
- Statins
- Aspirin (frequently deliberately combined in MPN)
- Anticoagulants (warfarin, DOACs) - no specific interaction; monitor INR on warfarin
- Standard vitamins including folic acid
The everyday reminder
Tell every pharmacist and every doctor that you take Hydrea. Over-the-counter medications and supplements should be checked - some "immune boosters" and herbal formulations either interact with the drug or affect the myelosuppression picture.
⏱️ What to Do If You Miss Hydrea
Missing an occasional Hydrea dose is common over years of therapy and usually causes no immediate problem. The pattern of adherence matters more than any single miss.
The rule
- Within 12 hours of usual time: take the missed dose now
- More than 12 hours late: skip it, take the next dose at usual time
- Never double up
- One missed dose has minimal clinical consequence
- Missing multiple days regularly undermines HbF response in sickle cell or count control in MPN
Longer gaps
- Missed a week: restart at usual dose
- Missed 2-4 weeks: restart at usual dose; contact treating team at next opportunity
- Stopped for months: call before restarting; team may want fresh baseline bloods
- In sickle cell, HbF drift back down over weeks after stopping; symptoms may return over months
When missed doses become a pattern
Frequent missed doses signal a bigger issue. Possible causes and solutions:
- 🔴 Side effects making the drug unpleasant - discuss dose reduction or symptom management
- 🔴 Adherence system failure - upgrade the reminder approach (pillbox, alarms, family cross-check)
- 🔴 Cost issues - discuss with pharmacy; generic hydroxyurea is cheap in most markets
- 🔴 Ambivalence about long-term therapy - honest conversation with treating team
Do not silently stop Hydrea because of adherence difficulty. Talking with the treating team almost always beats silent dropout - there are usually solutions.
👵 Hydrea in Older Adults and Frailty
Older adults on Hydrea are common - MPN clients particularly tend to be over 60 at diagnosis, and long-term sickle cell clients now reach older age thanks to improved care. Age-related considerations apply.
What changes with age
- Renal function declines with age - dose needs adjustment as eGFR falls
- Baseline haematological reserve lower - cytopenia more consequential
- Falls risk higher if fatigue increases
- Cardiovascular comorbidity common - particularly relevant in MPN
- Polypharmacy interactions rise
- Skin fragility increases - leg ulcer risk higher
- Long-term skin cancer surveillance more important
Practical adjustments
- Lower starting dose - often 500 mg once daily rather than weight-based higher
- Renal function-based dose adjustment - reduce for eGFR under 60
- More frequent blood count monitoring, especially during titration
- Attention to leg skin care - twice-daily moisturiser
- Regular dermatology review for skin cancer surveillance
- Simplify medication regimens where possible
- Cardiovascular risk factor management alongside MPN care
Frailty over age
Age alone is a poor guide to what clients tolerate. A fit 78-year-old with polycythemia vera can continue Hydrea indefinitely. A frail 68-year-old with multiple comorbidities may struggle with monitoring demands or side effects. Individual assessment guides the plan.
🤒 Sick Days and Infections on Hydrea
Hydrea can usually be continued through routine illness. Some specific situations warrant a pause or adjustment.
Common sick days
- Cold, flu, mild viral illness: continue if you can keep tablets down
- Stomach bug with vomiting: hold temporarily if you cannot keep tablets down for over 24 hours
- Fever without fluid loss: continue normally but check blood count if any concern
- Bacterial infection needing antibiotics: usually continue Hydrea; ensure counts are adequate
Neutropenic fever is an emergency
If your neutrophil count is low (typically under 1.0 x10^9/L) and you develop fever above 38 C, this is a medical emergency. Contact the treating team immediately. Do not wait to see if it settles. Broad-spectrum antibiotics within hours are essential.
Sickle cell specific concerns
In sickle cell disease, infection is a major trigger of pain crises and acute chest syndrome. Fever needs prompt evaluation. Dehydration during illness can trigger crises. Aggressive hydration during any illness is important. Continue Hydrea unless specifically told to stop.
Hospital admissions
- Tell the admitting team you are on Hydrea
- Blood counts on admission if not recently checked
- Continue Hydrea unless team advises otherwise
- Watch for interactions with new medications
- Sickle cell clients need pain management, hydration, oxygen if hypoxic
👶 Hydrea in Children and Adolescents
Paediatric use of Hydrea is a major indication - sickle cell disease starts at birth, and the FDA extended approval to children in 2017 following the BABY HUG trial. Paediatric considerations differ meaningfully from adult use.
Main paediatric indications
- Sickle cell disease - from 9 months of age; current guidelines recommend for all children with sickle cell anaemia (HbSS or HbS beta-zero thalassaemia)
- Paediatric CML - rare, but Hydrea used for initial cytoreduction
- Paediatric MPN - very rare
- Cytoreduction in paediatric leukaemia - occasional
The BABY HUG evidence
BABY HUG (Wang et al. Lancet 2011) enrolled 193 infants aged 9-18 months with sickle cell anaemia and demonstrated hydroxyurea is safe and effective in this youngest paediatric population. It reduced pain, dactylitis, acute chest syndrome, transfusion needs, and hospitalisation. Growth was preserved. This trial extended the indication and changed global paediatric practice.
Paediatric dosing
- Starting dose 20 mg/kg/day once daily
- Escalation to maximum tolerated dose up to 35 mg/kg/day
- Blood counts every 2 weeks initially, then monthly, then every 2-3 months when stable
- HbF measurement every 3-6 months
- Growth and development monitoring
Practical family guidance
- Give at the same time each day
- Siklos tablets (paediatric formulation) can be halved
- Standard Hydrea capsules should NOT be opened by families - specialist compounding needed for children unable to swallow
- Keep out of reach of siblings - cytotoxic
- Attend all blood test appointments
- Report fever above 38 C, unusual bruising, new lesions promptly
- Sun protection important; regular skin checks
- Long-term therapy - years to indefinite
Transition to adult care
Adolescents on Hydrea for sickle cell disease need structured transition to adult care. This transition often coincides with declining adherence and increased complications. Dedicated transition clinics improve outcomes substantially. Ensure the receiving adult team knows the full paediatric history including cumulative Hydrea exposure.
💉 Vaccinations and Immune Function on Hydrea
Vaccinations during Hydrea therapy need care. The drug is mildly immunosuppressive at therapeutic doses. Live vaccines carry risk; inactivated vaccines are important and safe.
Live vaccines - avoid
- 🔴 MMR (measles, mumps, rubella)
- 🔴 Varicella (chickenpox)
- 🔴 Live zoster (Zostavax - largely replaced by inactivated Shingrix)
- 🔴 Yellow fever
- 🔴 BCG
- 🔴 Oral polio
- 🔴 Live nasal flu (use injectable instead)
- 🔴 Rotavirus in infants
- 🔴 Oral typhoid (Ty21a)
Inactivated vaccines - safe and important
- 🟢 Annual flu vaccine (inactivated injection) - strongly recommended
- 🟢 Pneumococcal (PCV13 and PPV23) - important; sickle cell clients particularly vulnerable to pneumococcal disease
- 🟢 Meningococcal (ACWY and B) - important for sickle cell (splenic dysfunction)
- 🟢 COVID-19 vaccines
- 🟢 Shingrix (recombinant zoster) - safe
- 🟢 Hepatitis B (if not already immune)
- 🟢 Haemophilus influenzae B (Hib) - important for sickle cell
- 🟢 HPV in appropriate age groups
- 🟢 Tdap
Sickle cell disease-specific vaccine priority
Sickle cell clients have functional asplenia and are particularly vulnerable to encapsulated bacterial infections. Beyond routine schedules, sickle cell adults should have PPV23 pneumococcal boosters, meningococcal ACWY and B, and stay current with flu vaccination. These are more urgent than in the general population.
Timing: where possible, vaccinate before starting long-term Hydrea for better immune response. During therapy, still worth giving inactivated vaccines - reduced but real response. Household contacts should be up to date to protect the immunocompromised member.
🚫 Pregnancy Concerns With Hydrea Therapy
Hydrea is teratogenic in animal studies and carries documented human harm. Pregnancy during therapy is contraindicated, and contraception is mandatory throughout.
Fetal risks of Hydrea exposure
- Teratogenic in animal studies - skeletal, palatal, cardiac malformations
- Documented human case reports of malformation after first-trimester exposure
- Fetal growth restriction
- Preterm delivery
- Second and third trimester exposure: bone marrow suppression in neonate
Contraception rules
- Women of reproductive age: reliable contraception during Hydrea and for at least 6-12 months after
- Men of reproductive age: reliable contraception during therapy and for at least 6 months after (sperm damage recovery time)
- Barrier plus another method often recommended
- IUDs, hormonal contraception, barrier methods depending on individual context
Planning pregnancy in sickle cell disease clients
This is a specific challenge. Sickle cell disease itself carries pregnancy risks (higher miscarriage, preterm delivery, thrombosis, worsened crises). Hydroxyurea benefits during pregnancy would be significant. But the drug's teratogenicity means it must be stopped before conception. The consensus approach:
- Discuss pregnancy plans well before conception
- Stop Hydrea 3-6 months before attempting pregnancy
- Consider prophylactic transfusion during pregnancy in high-risk clients
- Restart Hydrea after breastfeeding is complete
- Multidisciplinary care with haematology, maternal-fetal medicine, and obstetrics
If pregnancy is confirmed on Hydrea
- Contact the treating team immediately
- Do not stop Hydrea without medical guidance - abrupt sickle cell decompensation is a concern
- Urgent referral to maternal-fetal medicine specialist
- Discussion of continuation versus stopping based on gestational age and individual circumstances
- Detailed fetal imaging if pregnancy continues
- Alternative management plan (transfusion for sickle cell) usually replaces Hydrea for the remainder of pregnancy
🍼 Breastfeeding While Taking Hydrea Therapy
Hydroxyurea passes into breast milk. Breastfeeding during Hydrea therapy is not compatible - the drug reaches the infant and can cause bone marrow suppression, though the amounts transferred are relatively small.
The position
- 🔴 Breastfeeding while taking Hydrea is not recommended
- 🔴 Manufacturer advises discontinuing either the drug or nursing
- 🔴 Practical approach: complete breastfeeding first, then restart Hydrea after weaning
- 🔴 For clients where Hydrea is essential (severe sickle cell, MPN), formula feeding is the safe alternative
Practical steps
- Discuss weaning plans at prenatal appointments if Hydrea restart is planned postpartum
- Milk suppression options (cabergoline) if needed after brief breastfeeding
- Formula feeding or expressed milk from donor bank as alternatives
- Some sickle cell clients delay restarting Hydrea until end of breastfeeding period (uses transfusion in interim)
- Pediatrician awareness of the situation
The decision balances the mother's need for Hydrea against benefits of breastfeeding. For most Hydrea indications the drug is important enough that formula feeding is the answer. Discuss the plan with the treating team well before delivery.
📆 Duration of Hydrea Therapy and Monitoring
Hydrea is often lifelong therapy in sickle cell disease and MPN. Duration and ongoing monitoring are worth understanding to make years of treatment sustainable.
Typical durations by indication
| Indication | Duration |
|---|---|
| Sickle cell disease | Indefinite; often lifelong from childhood |
| Polycythemia vera / ET | Indefinite; lifelong for higher-risk clients |
| CML initial cytoreduction | Days to weeks; then TKI takes over |
| CML maintenance (where TKI unavailable) | Indefinite |
| Acute leukaemia cytoreduction | Days before definitive chemotherapy |
Long-term monitoring rhythm
- Full blood count every 2-3 months once stable
- Renal function every 3-6 months
- Liver function periodically
- HbF percentage every 3-6 months in sickle cell
- Yearly full skin surveillance
- Cardiovascular risk assessment in MPN
- MPN clients: watch for disease progression signs (splenomegaly, worsening symptoms)
Reasons to stop Hydrea
- Persistent unmanageable cytopenia despite dose adjustment
- Non-healing leg ulcer
- Development of drug fever or pulmonary toxicity
- Development of secondary malignancy
- Pregnancy planning
- Loss of therapeutic effect (Section 31)
- Client preference after informed discussion
- Cure via stem cell transplant or gene therapy in sickle cell disease
Stopping Hydrea is a clinical decision, not something to do quietly. In sickle cell disease especially, stopping without alternative therapy risks return of crises and hospital admissions.
🔄 Switching From Hydrea to Newer Agents
Switching from Hydrea to other therapies happens for a variety of reasons - intolerance, inadequate response, disease progression, or the arrival of newer options.
Newer options in sickle cell disease
- L-glutamine (Endari) - approved 2017; oral; reduces crises modestly; can be added to Hydrea
- Voxelotor (Oxbryta) - approved 2019; increases haemoglobin oxygen affinity; recently voluntarily withdrawn in 2024 due to safety signals
- Crizanlizumab (Adakveo) - approved 2019; anti-P-selectin; reduces vaso-occlusive crises; withdrawn in EU after negative confirmatory trial
- Gene therapies (Casgevy exa-cel, Lyfgenia lovo-cel) - approved 2023; potentially curative; limited access
- Haematopoietic stem cell transplant - long-established curative option for eligible clients with a matched donor
Newer options in MPN
- Ruxolitinib (Jakavi) - JAK inhibitor; second-line for polycythemia vera intolerant of or resistant to Hydrea; also myelofibrosis
- Ropeginterferon alfa-2b (Besremi) - approved 2021 for polycythemia vera; long-acting interferon; alternative first-line
- Anagrelide - alternative for essential thrombocythemia when Hydrea not tolerated
- Fedratinib, momelotinib - newer JAK inhibitors for myelofibrosis
Hydroxyurea resistance and intolerance criteria
In polycythemia vera and ET, "resistance/intolerance" to hydroxyurea triggers switch to second-line therapy. ELN definitions include:
- Need for phlebotomy despite Hydrea 2 g/day for 3 months
- Uncontrolled myeloproliferation (platelets over 400, WBC over 10) despite adequate dose
- Failure to reduce massive splenomegaly
- Absolute neutrophil count below 1.0 or platelets below 100 at lowest dose required for response
- Leg ulcers or other non-haematological toxicity at any dose
The switch conversation is a specialist decision. For sickle cell disease particularly, newer therapies are important but access remains limited globally. Hydrea remains the foundation of sickle cell care for most clients worldwide.
🛑 Hydrea Contraindications - When to Avoid
Situations where Hydrea must not be given.
Absolute contraindications
- Known hypersensitivity to hydroxyurea
- Pregnancy - teratogenic
- Breastfeeding - drug transfers
- Severe bone marrow suppression at baseline - neutrophils under 1.5 or platelets under 100 depending on indication
- Prior severe hypersensitivity reaction to hydroxyurea
Relative contraindications
- Severe renal impairment - dose reduction essential
- Severe hepatic impairment
- Active infection - stabilise first
- Prior pulmonary toxicity from any drug
- Non-healing leg ulcer
- Prior secondary malignancy from cytotoxic exposure
- Inability to comply with monitoring
Reasons to stop Hydrea permanently
- Drug fever or pulmonary toxicity
- Severe cytopenia unresponsive to dose reduction
- Non-healing leg ulcer
- Development of secondary MDS/AML
- New skin cancer where cumulative exposure is high
- Pregnancy planning
- Cure via stem cell transplant or gene therapy in sickle cell
Do not stop Hydrea on your own without discussion. Especially in sickle cell disease and MPN, sudden cessation risks disease flare.
📦 Storage, Travel, Surgery and Yearly Review
Final practical topics for long-term Hydrea therapy.
Storage
- Room temperature under 25 C, in original packaging
- Protect from light and moisture
- Not in bathroom
- Not in hot car
- Out of reach of children and pets - cytotoxic
- Do not use past expiry
- Return unused capsules to pharmacy - cytotoxic waste stream
Travel
- Pack in hand luggage, not checked
- Take 30 percent extra supply
- Original packaging with pharmacy label for customs
- Travel letter from treating team for long trips
- Time zones - shift dose gradually if change over 4 hours
- Hot climates and dehydration - critical for sickle cell clients to hydrate aggressively
- Vaccinations - no live vaccines; discuss travel destinations with team
- Travel insurance - declare disease and current therapy
Surgery on Hydrea
- Tell every surgeon and anaesthetist
- Blood count check before elective surgery
- Some elective surgery may need brief hold if counts are borderline
- Sickle cell clients need specific perioperative management - transfusion planning, oxygen, hydration
- Wound healing may be modestly slower
- Coordinate with treating team on timing
Yearly review checklist
- Full blood count and reticulocytes
- Renal function (creatinine, eGFR)
- Liver function tests
- HbF in sickle cell clients
- Uric acid
- Full skin surveillance
- Leg check for ulcers
- Symptom review and adherence honest conversation
- Cardiovascular risk assessment in MPN
- Age-appropriate cancer screening
- Vaccination status update
- Any new medications - interaction check
- Whether to continue, adjust, or switch therapy
A closing thought
Hydrea is one of the most useful drugs in haematology - simple, oral, cheap, and effective across diseases as different as sickle cell disease and polycythemia vera. In sickle cell disease it has extended life for hundreds of thousands of people globally. In MPN it prevents strokes and heart attacks in a population that would otherwise face repeated thromboses. Taken faithfully with proper blood count monitoring, sun protection, and skin surveillance, it delivers meaningful benefit over years or decades. It remains one of the WHO Essential Medicines for good reason.
Hydrea — Frequently Asked Questions
-
What is Hydrea?
Hydrea (Hydroxyurea) is a medication used for treating certain cancers and sickle cell anemia. -
How does Hydrea work?
It works by inhibiting DNA synthesis, which slows down the growth of cancer cells and modifies sickle cell disease processes. -
What conditions is Hydrea used to treat?
It's used for chronic myeloid leukemia, certain head and neck cancers, and sickle cell anemia. -
How is Hydrea administered?
Hydrea is an oral medication, typically taken in capsule form. -
What is the usual dosage for Hydrea?
Dosage varies based on the condition being treated and patient response. It's crucial to follow your doctor's prescription. -
Can Hydrea be used in children?
Its use in children, particularly for sickle cell anemia, should be under strict medical supervision. -
What are the side effects of Hydrea?
Common side effects include nausea, vomiting, loss of appetite, and mouth sores.
📚 Drug Description Sources:
The information in this Hydrea (hydroxyurea, also called hydroxycarbamide) guide is drawn from pharmaceutical, medical, and regulatory sources covering sickle cell disease, myeloproliferative neoplasms, chronic myeloid leukaemia, and haematology practice. Content reflects nearly six decades of clinical experience since hydroxyurea's first US FDA approval in 1967 for cancer, and its later transformation into the primary disease-modifying drug for sickle cell disease after the landmark MSH trial in the 1990s.
🏛️ Regulatory and government agencies
- FDA (US Food and Drug Administration) - hydroxyurea US approval 1967 as Hydrea (Bristol-Myers Squibb, now Baxter) for cancer; 1998 approval for adult sickle cell disease; 2017 approval extended to paediatric sickle cell disease (Siklos); current DailyMed prescribing information
- EMA (European Medicines Agency) - hydroxycarbamide European authorisation; Siklos (paediatric sickle cell) authorised
- MHRA (UK Medicines and Healthcare products Regulatory Agency) - hydroxycarbamide summary of product characteristics
- Health Canada - Hydrea and hydroxyurea product monographs
- TGA (Australian Therapeutic Goods Administration) - hydroxyurea product information
- WHO Model List of Essential Medicines - hydroxyurea listed under antineoplastic medicines and separately for sickle cell disease
- IARC - hydroxyurea classified as Group 2A probable carcinogen; long-term surveillance relevant
📚 Professional societies and clinical guidelines
- NHLBI Sickle Cell Disease Guidelines (2014, updated) - hydroxyurea as disease-modifying therapy for adult and paediatric sickle cell
- ASH (American Society of Hematology) 2020 Guidelines on Sickle Cell Disease - hydroxyurea positioning updated
- BSH (British Society for Haematology) Guidelines - UK sickle cell and MPN management
- ELN (European LeukemiaNet) 2018 MPN Guidelines - hydroxyurea in polycythemia vera and essential thrombocythemia
- NCCN Guidelines: Myeloproliferative Neoplasms - hydroxyurea first-line cytoreduction
- ELN 2020 CML Guidelines - hydroxyurea for chronic phase CML in specific contexts (largely superseded by TKIs)
- WHO Model Formulary - hydroxyurea global positioning
🔬 Landmark clinical research
- Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH, Charache et al. NEJM 1995) - 299 adults with sickle cell disease; hydroxyurea reduced painful crises by 50 percent and blood transfusions by half; established the drug as first disease-modifying therapy for SCD
- MSH Long-Term Follow-Up (Steinberg et al. Am J Hematol 2010) - 40 percent reduction in mortality over 17.5 years follow-up
- BABY HUG Trial (Wang et al. Lancet 2011) - 193 infants aged 9-18 months with sickle cell; hydroxyurea safe and effective in the youngest paediatric population
- ECLAP Trial (Landolfi et al. NEJM 2004) - polycythemia vera trial establishing aspirin plus cytoreduction (often hydroxyurea) as standard
- Cortelazzo et al. NEJM 1995 - hydroxyurea in essential thrombocythemia; reduced thrombotic events
- PT-1 Trial (Harrison et al. NEJM 2005) - hydroxyurea versus anagrelide in essential thrombocythemia; hydroxyurea superior for arterial thrombosis prevention
- REACH Trial (Tshilolo et al. NEJM 2019) - hydroxyurea safety and efficacy in African children with sickle cell disease
📖 Medical references and textbooks
- Williams Hematology - the standard haematology reference; sickle cell and MPN chapters
- Wintrobe's Clinical Hematology - definitive haematology reference
- Steinberg, Forget, Higgs, Weatherall Disorders of Hemoglobin - dedicated haemoglobinopathy reference
- DeVita, Hellman and Rosenberg's Cancer Principles and Practice of Oncology - MPN and CML chapters
- Goodman and Gilman Pharmacological Basis of Therapeutics - antimetabolite pharmacology
- Harrison's Principles of Internal Medicine - haematology chapters
- UpToDate - hydroxyurea clinical monographs across indications
- Lexicomp and Micromedex - drug interactions and dosing databases
Note: This information is educational and does not replace consultation with a haematologist or oncologist. Hydroxyurea requires regular blood count monitoring throughout therapy. Always follow the treating team's instructions and report symptoms promptly.
🩺 Medical Expert Review:
Content based on the published research and clinical practice of authorities in sickle cell disease, myeloproliferative neoplasms, and paediatric haematology - the three main disciplines where hydroxyurea sits in daily practice. The following experts represent authoritative research and clinical practice perspectives on Hydrea use across its full range of indications.
Prof. Martin H. Steinberg, MD
Professor of Medicine, Pathology and Laboratory Medicine; Chief, Section of Hematology and Medical Oncology, Boston University School of Medicine — Boston, Massachusetts, USA
Prof. Steinberg is one of the world's most cited sickle cell disease researchers and has been central to the story of fetal haemoglobin induction with hydroxyurea. He led the MSH long-term follow-up study demonstrating a 40 percent mortality reduction over 17.5 years. His scholarship on haemoglobin switching, HbF pharmacology, and hydroxyurea response prediction has directly shaped how the drug is used in sickle cell disease worldwide.
Prof. Russell E. Ware, MD, PhD
Marjorie Johnson Endowed Chair in Pediatric Hematology; Director, Division of Hematology, Cincinnati Children's Hospital Medical Center; Professor, University of Cincinnati College of Medicine — Cincinnati, Ohio, USA
Prof. Ware led the BABY HUG trial which established hydroxyurea safety and efficacy in infants aged 9-18 months with sickle cell disease. He also led the REACH trial studying hydroxyurea in African children. His scholarship on paediatric hydroxyurea dosing, safety, and disease modification directly informs global sickle cell practice from newborn screening through adulthood.
Prof. Julie Kanter, MD
Director, Adult Sickle Cell Program; Associate Professor of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham — Birmingham, Alabama, USA
Prof. Kanter is a leading US voice on contemporary adult sickle cell disease care and served on the ASH 2020 Sickle Cell Disease Guideline writing committee. She has led trials of newer sickle cell therapies (voxelotor, crizanlizumab, gene therapies) alongside hydroxyurea. Her scholarship on combining hydroxyurea with newer agents and transitioning between them has directly informed contemporary US practice.
Prof. Tiziano Barbui, MD
Scientific Director, Foundation for Research (FROM), Papa Giovanni XXIII Hospital; formerly Chairman, Department of Haematology — Bergamo, Italy
Prof. Barbui has been a central figure in myeloproliferative neoplasm research for four decades. He led the ECLAP trial that established modern polycythemia vera management, and co-founded the European LeukemiaNet MPN research network. His scholarship on hydroxyurea positioning in polycythemia vera and essential thrombocythemia, thrombosis prevention, and disease progression has directly shaped ELN and NCCN guidelines.
Prof. Alessandro M. Vannucchi, MD
Professor of Hematology and Director, CRIMM (Center for Research and Innovation of Myeloproliferative Neoplasms), Careggi University Hospital, University of Florence — Florence, Italy
Prof. Vannucchi directs one of Europe's largest MPN research centres and has published more than 500 peer-reviewed papers on myeloproliferative disease. He has led numerous trials of ruxolitinib and other JAK inhibitors alongside hydroxyurea. His scholarship on hydroxyurea resistance, intolerance, and the switch to second-line agents has substantially informed European clinical practice.
Disclosure: Expert names and credentials are cited for educational reference. This content is not endorsed by named experts. Content prepared by RXshop editorial team based on published literature and clinical guidelines.
More Cancer Medications
